131895-50-6 Usage
Description
4-Pyridinecarbonitrile,2,3-dimethyl-(9CI) is an organic compound characterized by its pyridine ring structure with two methyl groups at the 2nd and 3rd positions and a nitrile group at the 4th position. It serves as a crucial intermediate in the synthesis of various pharmaceutical compounds and agrochemicals due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
4-Pyridinecarbonitrile,2,3-dimethyl-(9CI) is used as an intermediate for the development of subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors. These modulators play a significant role in treating various medical conditions, such as hypertension, anxiety, and depression, by targeting specific adrenergic receptor subtypes and modulating their activity.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Pyridinecarbonitrile,2,3-dimethyl-(9CI) is utilized in the synthesis of pyridylmethylsulfonamides, which are effective fungicides. These fungicides are employed to protect crops from fungal infections, ensuring higher crop yields and better quality produce. The compound's unique structure allows for the development of targeted and effective antifungal agents, contributing to improved agricultural practices and crop protection.
Check Digit Verification of cas no
The CAS Registry Mumber 131895-50-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,8,9 and 5 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 131895-50:
(8*1)+(7*3)+(6*1)+(5*8)+(4*9)+(3*5)+(2*5)+(1*0)=136
136 % 10 = 6
So 131895-50-6 is a valid CAS Registry Number.
131895-50-6Relevant articles and documents
PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS
-
Page/Page column 11, (2010/08/18)
The invention relates specifically to the use of certain 4-[1-(1H-Imidazol-4-yl)-ethyl]-2,3-substituted pyridine compounds and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation.
